Table 1.
Baseline characteristics of patients with primary intraocular lymphoma treated with intravitreal methotrexate (MTX) and systemic high‐dose MTX
| Intravitreal and systemic high‐dose MTX (n = 10) | |
|---|---|
| Age, years | |
| Median (range) | 68.5 (46–78) |
| Sex, n (%) | |
| Male | 4 (40) |
| Female | 6 (60) |
| Laterality, n (%) | |
| Unilateral | 3 (30) |
| Bilateral | 7 (70) |
| Initial symptoms, n (%)† | |
| Blurred vision | 8 (80) |
| Visual loss | 3 (30) |
| Floaters | 2 (20) |
| Photopsia | 1 (10) |
| Time to diagnosis, months | |
| Median (range) | 8 (4–18) |
| Disease type, n (%) | |
| Vitreous type | 7 (70) |
| Subretinal type | 0 (0) |
| Mixed type | 3 (30) |
| Cytology, n (%)‡ | |
| Positive | 7 (70) |
| Flow cytometry, n (%)‡ | |
| B‐cell monoclonality (+) | 8 (80) |
| IGH rearrangement, n (%)‡ | |
| Positive | 6 (60) |
| Cytokine analysis | |
| IL‐10, pg/mL, median (range) | 1348 (0–3544) |
| IL‐10/IL‐6 > 1, n (%)‡ | 9 (90) |
†Some patients had >1 initial symptom. ‡Ratio = number of positive cases/total number of cases examined. IGH, immunoglobulin heavy chain; IL, interleukin.